Journal of Clinical Pharmacology 2001: Vol 41 Index

13 Pages·2001·4.3 MB·English

Ford, N. F., 742 Hewitt, R. G., 435 Katz, R., 118S Lawrenson, R. A., 852
Fowler, J. S., 9S Hguyen, H. H., 612 Kaul, S., 833 Ledford, P. C., 1131
Fox, A. W., 259 Hinderling, P. H., 35 Kearns, G. L., 612, 846, 1359 Lee, J. W., 199
Fox, B. A., 81S Hinson, J. A., 846 Kelly, J., 950 Lee, M., 317
Frackiewicz, E. J., 1351 Hirooka, K., 157 Kempsford, R. D., 170 Leese, P. T., 1232, 1301
Frank, R., 4S, 107S, 118S Hochaus, G., 536 Kerkering, T. M., 386 Lefrant, J-Y., 44
Freed, M. I., 683 Hochhaus, G., 425, 1329 Ketel, B. L., 113 Legayada, E., 620
Frick, M., 542 Hochhaus, R., 425 Khalilieh, S., 987 Lens, S., 107
Fuder, H., 950 Hogg, R., 1064 Khoo, K-C., 1359 Lesko, L., 1082
Fulmor, I. E., 1351 Holmes, G. B., 1120 Kildoo, C., 92 Levasseur, L. M., 452
Fung, J. J., 268 Homma, Y., 1055 Kim, J. S., 715 Lever, J., 268
Fuseau, E., 170 Hon, Y. Y., 1059 King, S. P., 1206 Levy, G., 655
Hopkins, N. K., 552, 563 Kirch, W., 51 Li, T-K., 1345
Gaedigk, A., 715 Horowitz, A., 1131 Kirkesseli, S., 305 Liao, W-C., 833, 1280, 1291
Gaffney, M., 1215 Hu, H-M., 81S Klapholz, M., 1280 Lindley, C., 723
Gagliano, K., 573 Hu, W., 187 Klassen, D. K., 861 Lins, R., 107
Gallini, F., 1075 Hubbard, R. C., 1111 Kleerekoper, M., 239 Linnet, K., 823
Garreffa, S., 127 Hubert, M., 1131 Kline, S., 963 Lipka, L., 943
Gertz, B. J., 107, 1120 Hui, C-K., 691 Klockowski, P. M., 443 Lipka, L. J., 70
Giancarlo, G. M., 85 Hunninghake, D. B., 70 Knopp, R., 70 Liu, H., 1206
Gillen, M. S., 7 Hutman, H. W., 277 Knop-Schneickert, E., 668 Liu, L., 573
Givens, T. G., 846 Knupp, C. A., 833 Liu, P., 330
Gobbura, J. V. S., 1082 Incerti, C., 193, 199 Kobayahi, T., 1055 Lizak, P., 1091
Goldberg, A. C., 70 Inglis, A. M. L., 683 Koch, K. M., 452, 455 Lo, M-W., 1064
Gorsline, J., 655 Innis, R., 107S Kollia, G. D., 935, 1280, 1351 Lou, Y., 277, 386
Gottesdiener, K. M., 1106 Ishida, S., 459 Kook, K. A., 662 Ludden, T. M., 415
Graefe, E. U., 492 Ito, M. K., 779 Koren, G., 842 Luke, D., 210
Graf, J. A., 1043 luliucci, J. D., 870 Kornblum, H. I., 55S Luo, Y., 305
Graff, D. W., 97, 723 Iyer, R. A., 833 Korth-Bradley, J., 979, 1206 Luzier, A. B., 750
Gramatté, T., 51 Izzo, J. L., 750 Kosoglou, T., 943
Granda, B. W., 85 Kostis, J. B., 935, 1280 MacFarlane, G., 542
Granneman, G. R., 397 Jacobasch, G., 492 Kovar, A., 139, 585 MacRae, K. D., 852
Grant, E. M., 206 Jacobson, J., 1091 Krieg, M., 536, 1329 Magee, M. H., 1180
Greenblatt, D. J., 85, 708, 1043, 1149 Jahnchen, E..79 Krishnaswami, S., 1329 Maggio, L., 1075
Griffith, B. P., 1271 Jain, A., 268 Krohn, K. A., 96S Mahmood, I., 19
Groen, H. J. M., 48S Jain, A. B., 542, 1271 Krzyzanski, W., 251 Mahony, W. B., 277
Grossmann, M., 51 James, L. P., 846 Ku, Y-M., 317 Malhotra, B. K., 833, 972
Gupta, S. K., 187 Jann, M. W., 1059 Kudolo, G. B., 600 Manaligod, J. M., 1225
Gurley, B. J., 113, 1059 Jayewardene, A., 1091 Kuss, M. E., 1111 Mankoff, D. A., 96S
Gusler, G., 655 Jemal, M., 1280 Kuwert, T., 118S Manning, J. A., 1280, 1291
Jensen, B. K., 61 Kuznetsova, O., 573 Manno, J. E., 770
Hadjilambris, O. W., 742, 935 Jensen, S., 81S Kwo, P. Y., 1345 Marino, M. R., 742, 935
Haig, G. W., 507 Jhee, S. S., 1082 Masonson, H. N., 515
Hak, L. J., 170 Johannessen, M., 880 LaBoy-Goral, L., 1339 Matsumoto, K., 459
Halldin, C., 95S Johansson, C., 298 Laham, R. J., 378 Matthews, C. Z., 1106
Halstenson, C., 183 Johnson, M. A., 732 Lai, C-L., 691 Mayer, P. R., 149
Hamad, I. S., 268 Jones, A., 1098 Lammertsma, A. A., 104S McCune, J. S., 723
Hand, E., 1064 Jones, A. E., 528 Lane, J. R., 259, 927 McFeely, E. J., 927
Hannerz, J., 465 Jones, P., 70 Larsen, F., 340 McKeand, W., 149
Harding, N., 404 Jorkasky, D. K., 683 Larson, P. J., 107 McLean, A., 183
Hardman, T. C., 1098 Jusko, W. J., 251, 1180, 1195 Larson, P., 612 McLeod, J. F., 987, 1131
Harmatz, J. S., 85, 1043 Justice, L., 81S Lasseter, K., 573, 987 McNamara, D. R., 374
Hashimoto, H., 459 Lates, C. D., 1180 Meadowcroft, A. M., 723
Heintz, B., 79 Kamakura, S., 459 Lathers, C. M., 595, 1265 Metiuri, U., 415
Hellriegel, E. T., 895 Kapur, S., 64S Lathia, C., 764 Mehrotra, R., 81S
Hendershot, P. E., 552, 563 Karara, A. H., 35 Lau, C-P., 92 Meijer, S. L., 81S
Hendrikse, N. H., 48S Karim, A., 1111 Laurent, A., 1111 Mekki, Q. A., 176, 289, 628
Herscovitch, P., 11S Karpawich, P. P., 35 Lawlor, C., 1329 Melikian, A. P., 35
Mellars, L., 943 Otto; VR.3 Rettie, A. E., 715 Shomaker, T. S., 677
Menhinick, A. M., 374 Ouellet, D., 507 Rey, J., 404 Shoukri, M. M., 620
Meno-Tetang, G. M. L., 1195 Overg, K. F,, < Rhodes, G. R., 7 Sidhu, R., 305
Mertzanis, P., 1043 Riethling, A-K., 492 Simar, M. R., 770
Milisci, M., 979 Padhi, I. D., 1310 Rippley, R., 1064 Simms, L., 452, 455
Miller, A. K., 683 Padley, R. J., 397 Roadcap, B. A., 573 Simons, M., 378
Miller, J. L., 1106, 1120, 1225 Pakes, G. E., 732 Robbins, D. K., 452, 455 Sission, J. R., 528
Min, D. I., 317 Palmisano, M., 935, 972 Robertson, P., 895 Sitar, D. S., 757
Mineshita, S., 157 Panebianco, D., 1064 Rodarte, A., 1359 Skee, D. M., 1232, 1301
Mitroka, J. G., 833 Papacci, P., 1075 Rodrigues, A. D., 368 Slain, D., 386
Miyatake, K., 459 Parish, R. C., 770 Rodriguez, M. C., 1043 Slapak, C. A., 29S
Mdllmann, A. C., 536, 1329 Pasquier, O., 404 Rogers, J. D., 573, 612 Slater, M. E., 1111
Molimann, H., 425, 536, 1329 Patrick, J., 943 Rohatagi, S., 7, 61 Slaughter, E., 183
Montay, G., 404 Patterson, J. H., 97 Romagnoli, C., 1075 Slugg, P., 742
Moodley, D., 732 Patterson, S. D., 683, 811 Romanowski, G. L., 927 Smith, C. M., 1265
Moodley, J., 732 Paulus, S., 959 Rosebraugh, C. J., 224 Smith, J. W., 81S
Moore, K. H. P., 386, 528, 732, 1098 Payer, A., 1265 Rosenheim, S., 81S Snyder, B. D., 750
Moretti, M. E., 842 Penzak, S. R., 1059 Rosman, H., 1310 Sogaard, B., 163
Morley, S., 870 Perloff, M. D., 708 Rouzier-Panis, R., 404 Soucek, K. M., 833
Morse, T., 1339 Pesco-Koplowitz, L Rudy, A. C., 1225 Sousa, P., 927
Moudgil, T., 81S Petermann, F., 668 Ryan, K. K., 217 Spielberg, S., 612
Mudd, P.N., 732 Peters, T., 139, 585 Spritzler, J., 1091
Mueller, S., 492 Pforte, H., 492 Sack, M. R., 1120 Sramek, J. J., 1082, 1351
Miihlbauer, K., 668 Phelps, S. J., 170 Sadler, B. M., 386 Stambaugh, H., 500
Miihlig, S., 668 Pieniaszek, H. J., 479 Sakarcan, A., 742, 1064 Stambaugh, J. E., 500
Mukherjee, A., 415 Pieper, J. A., 97, 723 Sakr, A., 783, 886 Stambaugh, M. D., 500
Mukhopadhyay, S., 1106 Pike, M., 378 Salazar, D. E., 1351 Statkevich, P., 943
Miiller, J. M., 668 Pillay, K., 732 Samara, E., 378, 397 Stein, D. S., 386
Mullins, R., 542 Pirsch, J., 542 Sarkozi, L., 542 Stein, E. A., 70
Murdoch, R. D., 950 Piwnica-Worms, D., 29S Sathyan, G., 187 Stern, R. C., 645
Murray, W., 927 Plone, M. A., 193, 199 Saul, J. P., 35 Stevens, J. C., 305
Musser, B., 573 Poehlein, C. H., 81S Sawyer, W. T., 723 Stewart, J. J., 742, 770
Polk, R. E., 386 Schaffer, M. S., 35 Stirling, D. 1., 662
Nafziger, A. N., 374, 715 Pommier, F., 987 Scheffler, M. R., 662 Stéckmann, R., 1329
Naidoo, K., 732 Porras, A. G., 107, 1106, 1120 Schein, J. R., 239 Stormer, E., 708
Naret, D., 655 Port, A., 950 Scheller, D., 542 Studenberg, S. D., 386
Natarajan, J., 1301 Posvar, E. L., 507 Schmider, J., 1043 Suarez, S., 425
Navioz, Y., 842 Pou, S., 1359 Schulz, M., 668 Sullivan, J. E., 846
Nelson, M., 895 Preston, R. A., 1215 Schwartz, J. B., 324 Sun, H., 25
Neu, D. C., 1106 Prince, W. T., 528, 1098 Schwartz, J. I., 107, 1120 Sundaresan, P., 330, 764
Nezamis, J., 452, 455 Priskorn, M., 340 Schwartz, K. E., 1195 Svendsen, K., 987
Nicolau, D. P., 206 Proskin, H., 127 Schwocho, L. R., 515 Syed, A., 770
Nightingale, Charles, 206 Prueksaritanont, T., 573 Scott, N., 1339
Nilsson, P., 880 Puchalski, T. A., 251 Seaman, H. E., 852 Takada, M., 459
Noveck, R., 972 Pumford, N. R., 846 Seiler, K-U, 79 Tammara, V., 1082
Novicki, D. L., 378 Puri, R., 81S Shader, R. I., 85, 1043 Tanaka, K., 459
Shah, A. K., 330, 764, 1339 Tang, M-O., 92
Odeh. M., 582 Qian, J., 1111 Shahinfar, S., 1064 Tang, Y., 1329
Oertel, R., 51 Quintiliani, R., 206 Shaked, A., 542 Tantillo, K., 979
Oh, J. M.,861 Shangold, M. M., 1301 Taylor, K., 443
Oi-Lin Ng, I., 691 Raines, D., 620 Sharma, N. D., 1310 Tenney, F., 742
Olesen, O. V., 823 Ramchandani, V. A., 1345 Shaw, L. M., 542 Teo, S. K., 662
Oliven, A., 582 Randinitis, E. J., 507 Shaw, W., 1064 Thomas, S. D., 662
Oliver, S. D., 870 Rasty, S., 1310 Shelton, M. J., 435 Thompson, K., 683
Olsson, B., 298 Reder, R. F., 500 Sheu, W-P., 552 Thompson, N. F., 277
Onyiah, L. C., 25 Redfern, J. S., 1120 Shi, J.,.35 Thomsen, M. S., 880
O’Riordan, M. A., 645 Reed, M. D., 645, 1359 Shibakawa, M., 459 Tigel, P. D., 1351
Osborne, S., 987, 1131 Reiss, T. F., 612 Shimizu, M., 157 Tisdale, J. E., 1310
Todorova, A., 636 Villaran, C., 612 Wermeling, D. P. H., 1225 Yamada, J., 81S
Tolley, E., 415 Virji, Mohammed, 542 Wesche, D. L., 507 Yasuda, S. U., 224
Tracewell, W. G., 662 VogBt., ,106 4 Weston, I. E., 655 Yates, C. R., 415
Tracey, I., 21S Volkow, N. D., 9S Wexler, D., 943 Ynddal, L., 163
Trapnell, C., 1091 Volle, R. L., 1265 White, C. M., 92 Yoshizawa, C., 378
Trenk, D., 79 von Moltke, L. L., 85, 708, 1043, 1149 Whitehouse, M. J., 378 Yuan, R., 1082
Tromm, A., 536 Vonderheid-Guth, B., 636 Wiland, A. M., 861 Yuen, G. J., 277
Tse, S., 979 Vysokanoy, A., 415 Williams, P., 25 Yuen, M-F., 691
Turkel, C. C., 259 Williams, P. B., Yusuf, A., 620
Wagner, H. N., 118S Williams, P. J., 25
Uderman, H. D., 1291, 1351 Wagner, M., 1329 Williams, T. J., Zannikos, P. N.,
Uehleke, B., 492 Wah-Tak Tsang, K., 691 Williamson, K. M., 97, 723 Zariffa, N. M-D.
Ueno, K., 459 Walker, E., 81S Wilson, J. T., 742, 770 Zarycranski, W.
Upward, J., 950 WalsT. hJ.,, 9 63 Winchell, G. A., 368 Zdravkovic, M.
Urba, W. J., 81S Walson, P., 1064 Winter, H., 81S Zecca, E., 1075
Walson, P. D., 846 Wisner, P., 81S Zeevi, A., 1271
Vaalburg, W., 48S Ward, C., 870 Wittig, J., 492 Zhang, J., 612, 677
Vachharajani, N. N., 742, 935 WarJd.,, 87 0 Wong, F. A., 1232, 1301 Zhang, S., 268
van der Graaf, W. T. A., 48S Warty, V. S., 268 Wong, P. H., 1120 Zhang, S. Z., 655
Vega, J. M., 573 Wasserman, G. S., 846 Wood, J., 81S Zhang, Y., 183
Veit, M., 492 Waterhouse, R., 4S Wood, W. J., 81S ZhaJo.,, 57 3
VeltrE.i, ,94 3 Watson, N., 193 Woodruff, M., 330 Zhao, Q., 1319
Venkatakrishnan, K., 1043, 1149 Webber, D. M., 950 Woolf, E. J., 1106 Zhong, M-K., 206
Venkataramanan, R., 268, 542 Weidle, P. J., 861 WoollJ.e Ly.,, 38 6 Zhou, H., 987, 1131, 1319
Verbesselt, R., 107 Weinberg, A. D., 81S Woosley, R. L., 224 Zuckerman, S., 268
Verheyen, F., 668 Wells, T., 1064 WylPd.,, 95 0 Zussman, B. D., 950
Vesterqvist, O., 1280, 1291 Wells, T. G., 742 Wynn, H. E., 435
VetJt. oT.,, 8 1S Welshman, I. R., 563
Subject Index, Volume 41 (2001)
Abacavir Amprenavir pharmacokinetics, safety, and tolerability of
abacavir/lamivudine/zidovudine as a combined metabolic disposition and pharmacokinetics of BAY 12-9566 and nonsteroidal anti-inflam-
formulation tablet: bioequivalence compared (“C]-amprenavir, a human immunodefi- matory agents (Naproxen, Ibuprofen) during
with each component administered concur- ciency virus type 1 (HIV-1) protease inhibi- coadministration in patients with
rently and the effect of food on absorption, tor, administered as a single oral dose to osteoarthritis, 330
277 healthy male subjects, 386 Bioavailability
Abstracts Analgesia bioavailability of the novel nonnucleoside re-
abstracts of the 30th annual meeting of the Amer- double-blind, randomized comparison of the verse transcriptase inhibitor GW-420867X
ican College of Clinical Pharmacology, 1014 analgesic and pharmacokinetic profiles of is unaffected by food in healthy male volun-
Acetaminophen controlled- and immediate-release oral teers, 528
oxycodone in cancer pain patients, 500 bioavailability and pharmacokinetics of loraze-
measurement of acetaminophen-protein adducts
in children and adolescents with aceta- Antilipolytic effects pam after intranasal, intravenous, and intra-
minophen overdoses, 846 pharmacokinetic-pharmacodynamic modeling muscular administration, 1225
Acid-suppressive therapy of the antilipolytic effects of an adenosine effect of time of meal consumption on bio-
receptor agonist in healthy volunteers, 61 availability of a single oral 5 mg tacrolimus
acid-suppressive therapy use associated with dose, 289
antihypertensive agents, 750 Anxiety disorders
food increases the bioavailability of tolterodine
African Americans pharmacokinetics and tolerability of buspirone but not effective exposure, 298
during oral administration to children and
effect of grapefruit juice on pharmacokinetics of adolescents with anxiety disorder and nor- influence of food on the bioavailability of a
microemulsion cyclosporine in African
mal healthy adults, 1351 twice-daily controlled release carbama-
American subjects compared with Cauca- zepine formulation, 183
sian subjects: does ethnic difference mat- Arthritis
oral bioavailability and disposition of [“C]oma-
ter?, 317 lack of pharmacokinetic interaction between
Age rofecoxib and methotrexate in rheumatoid patrilat in healthy subjects, 833
effect of age and gender on the safety, tolerability, arthritis patients, 1120 pharmacokinetics and bioavailability of quercetin
and pharmacokinetics of BAY 12-9566 in pharmacokinetics, safety, and tolerability of glycosides in humans, 492
healthy subjects, 764 BAY 12-9566 and nonsteroidal anti-inflam- pharmacokinetics and rectal bioavailability of
matory agents (Naproxen, Ibuprofen) during hydrocortisone acetate after single and mul-
race but not age affects erythromycin breath test
coadministration in patients with osteo- tiple administration in healthy subjects and
results in older hypertensive men, 324
arthritis, 330 patients, 536
Alcohol
Artrial fibrillation Bioequivalence
effect of food and food composition on alcohol
evaluation of CYP2D6 oxidation of dextro- population and individual bioequivalence: les-
elimination rates in healthy men and women,
methorphan and propafenone in a Chinese sons from real data and simulation studies,
1345 population with atrial fibrillation, 92 811
Almotriptan
Asthma Bucolome
evaluation of the potential pharmacokinetic in-
pharmaceutical care services for asthma pa- stereoselective effects of bucolome on the
teraction between almotriptan and fluoxetine tients: a controlled intervention study, 668 pharmacokinetics and pharmacodynamics
in healthy volunteers, 217
of racemic warfarin, 459
Alosetron Atorvastatin
Budesonide
effect of alosetron on the pharmacokinetics of the effects of converting from simvastatin to
alprazolam, 452 atorvastatin on plasminogen activator in- single-dose and steady-state pharmacokinetic
hibitor type-1, 779 and pharmacodynamic evaluation of thera-
effect of alosetron on the pharmacokinetics of peutically clinically equivalent doses of in-
fluoxetine, 455 Atracurium haled fluticasone propionate and budesonide,
Alprazolam pharmacokinetic/pharmacodynamic modeling given as Diskus® or Turbohaler® dry-pow-
effect of alosetron on the pharmacokinetics of of atracurium in intensive care patients, 44 der inhalers to healthy subjects, 1329
alprazolam, 452 Atrasentan Bupropion
Alzheimer’s disease single-dose pharmacokinetics of atrasentan, an single-dose pharmacokinetics of bupropion in
endothelin-A receptor antagonist, 397
pharmacokinetics-pharmacodynamic modeling adolescents: effects of smoking status and
on rivastigmine, a cholinesterase inhibitor, Azathioprine gender, 770
in patients with Alzheimer’s disease, 1082 comparison of azathioprine and mycophenolate Buspirone
mofetil for the prevention ofa cute rejection
AmBisome comparative multidose pharmacokinetic study
pharmacokinetics, excretion, and mass balance in recipients of pancreas transplantation, 861 of buspirone extended-release tablets with a
of “C after administration of “C-cholesterol- Azithromycin eference immediate-release product, 886
labeled ambisome to healthy volunteers, lack of an effect of azithromycin on the disposi- pharmacokinetics and tolerability of buspirone
963 tion of zidovudine and dideoxyinosine in during oral administration to children and
Amlodipine HIV-infected patients, 210 adolescents with anxiety disorder and nor-
comparative pharmacokinetics and pharmaco- BAY 12-9566 mal healthy adults, 1351
dynamics of amlodipine in hypertensive pa- effect of age and gender on the safety, tolerability, pharmacokinetics of buspirone extended-release
tients with and without type II diabetes and pharmacokinetics of BAY 12-9566 in tablets: a single-dose study, 783
mellitus, 1215 healthy subjects, 764
Caffeine CS-866 tients with and without type II diabetes
caffeine metabolism in premature infants, 620 pharmacokinetics of CS-866, a new angiotensis mellitus, 1215
Cancer II receptor blocker, in healthy patients, 515 effect of 3-month ingestion of ginkgo biloba ex-
double-blind randomized comparison of the an- Cyclosporine tract (EGb 761) on pancreatic B-cell function
algesic and pharmacokinetic profiles of con- effect of grapefruit juice on pharmacokinetics of in response to glucose loading in individu-
trolled-and immediate-release oral oxyco- microemulsion cyclosporine in African als with non-insulin-dependent diabetes
done in cancer pain patients, 500 American subjects compared with Cauca- mellitus, 600
pharmacokinetics of gemtuzumab ozogamicin, sian subjects: does ethnic difference mat- Dichloroacetate
an antibody-targeted chemotherapy agent for ter?, 317 population pharmacokinetics with a pharmaco-
the treatment of patients with acute myeloid Cystic fibrosis dynamic sequential link model, 259
leukemia in first relapse, 1206 pharmacokinetics of colistin in patients with Dideoxyinosine
Carbamazepine cystic fibrosis, 645 lack of an effect of azithromycin on the disposi-
the influence of food on the bioavailability of a CYP3A tion of zidovudine and dideoxyinosine in
twice-daily controlled release carbama- lack of correlation between in vitro inhibition of HIV-infected patients, 210
zepine formulation, 183 CYP3A-mediated metabolism by a PPAY-y Digoxin
Cellular proliferation agonist and its effect on the clinical decrease of intracranial pressure and weight
imaging cellular proliferation as a measure of re- pharmacokinetics of midazolam, an in vivo with digoxin in obesity, 465
sponse to therapy, 96S probe of CYP3A activity, 305 effect of rofecoxib on the pharmacokinetics of
Central nervous system relative contribution of CYP3A to amitri- digoxin in healthy volunteers, 107
effects of tolterondine, trospium chloride, and ptypline clearance in humans: in vitro and effects of tegaserod (HTF 919) on the pharmaco-
oxybutynin on the central nervous system, in vivo studies,1043 kinetics and pharmacodynamics of digoxin
636 Cytochrome P450 in healthy subjects, 1131
“FDG for the study of central nervous system human drug metabolism and the cytochromes lack of citalopram effect on oral digoxin pharm-
drugs, 9S P450: application and relevance of in vitro acokinetics, 340
Chinese models, 1149 Dimerizer drug
evaluation of CYP2D6 oxidation of dextro- lack of gender differences and large intrasubject intravenous safety and pharmacokinetics of a
methorphan and propafenone in a Chinese variability of cytochrome P450 activity mea- novel dimerizer drug AP1903, in healthy
population with atrial fibrillation, 92 sured by phenotyping with dextro- volunteers, 870
Cilomilast methorphan, 723 Disease progression
Dalfopristin
overview of the pharmacokinetics of cilomilast monitoring disease progression in Parkinson’s
(Ariflo®), a new, orally active phospho- multiple-dose pharmacokinetics and safety of disease, 72S
two regimens of quinupristin/dalfopristin
diesterase 4 inhibitor, in healthy young and Doxylamine
(Synercid®) in healthy volunteers, 404
elderly volunteers, 950 the safety of higher than standard dose of
Dexamethasone
Citalopram effect doxylamine-pyridoxine (Diclectin®)for
lack of citalopram effect on oral digoxin cardiac adverse effects of early dexamethasone nausea and vomiting of pregnancy, 842
treatment in preterm infants: a randomized
pharmacokinetics, 340 Drug development
clinical trial, 1075
Clozapine application of preclinical data to initiate the
Dexamethasone phoshate (DP)
contributions of five human cytochrome P450 modified continual reassessment method for
isoforms to the N-demethylation of pharmacokinetics and pharmacodynamics of maximum tolerated dose-finding trials, 19
dexamethasone sodium-m-sulfobenzoate
clozapine in vitro at low and high concen- fundamentals of positron emission tomography
trations, 823 (DS) after intravenous and intramuscular and applications in preclinical drug devel-
administration: a comparison with dexa-
Colistin opment, 482
methasone phoshate (DP), 425
pharmacokinetics of colistin in patients with in vitro and in vivo techniques used in drug de-
Dexamethasone sodium-m-sulfobenzoate (DS)
cyctic fibrosis, 645 velopment for evaluation of dose delivery of
pharmacokinetics and pharmacodynamics of inhaled corticosteroids, 7
Coma dexamethasone sodium-m-sulfobenzoate
population and individual bioequivalence: les-
coma and seizures due to severe hyponatremia (DS) after intravenous and intramuscular
and water intoxication in an adult with intra- administration: a comparison with dexa- sons from real data and simulation studies,
nasal desmopressin therapy for nocturnal- methasone phoshate (DP), 425 811
enuresis, 582 Dextromethorphan use of imaging as biomarkers in drug develop-
ment: regilatory issues worldwide, 118S
Coronary artery disease
effect of venlafaxine versus fluoxetine on me- use of in vitro drug metabolism data to evaluate
pharmacokinetics and pharmacodynamics of tabolism of dextromethorphan, a CYP2D6
recombinant FGF-2 ina phase I trial in coro- probe, 443 metabolic drug-drug interactions in man:
the need for quantitative databases, 368
nary artery disease, 378 evaluation of CYP2D6 oxidation of dextro-
Drug disposition
Corticosteroids methorphan and propafenone in a Chinese
in vitro and in vivo techniques used in drug de- population with atrial fibrillation, 92 lack of interaction between levofloxacin and
oxycodone: pharmacokinetics and drug
velopment for evaluation of dose delivery lack of gender differences and large intrasubject
on inhaled corticosteroids, 7 variability in cytochrome P450 activity dispostion, 206
Drug interactions
Cortisol suppression measured by phenotyping with dextro-
effects of oral prasterone (dehydroepiand- methorphan, 723 effect of alosetron on the pharmacokinetics of
alprazolam, 452
rosterone) on single-dose pharmacokinetics Diabetes
of oral prednisone and cortisol supression comparative pharmacokinetics and pharmaco- effect of alosetron on the pharmacokinetics of
in normal women, 1195 dynamics of amlodipine in hypertensive pa- fluoxetine, 455
effect of fluoxetine on carvedilol pharmaco- inhibition of human cytochrome P450 isoforms FFR-rF Vila
kinetics, CYP2D6 activity, and autonomic by nonnucleoside reverse transcriptase in- pharmacokinetics and safety of FFR-rF VIla after
balance in heart failure patients, 97 hibitors, 85 single doses in healthy subjects, 880
effect of rofecoxib on the pharmacokinetics of lack of correlation between in vitro inhibition of Floxetine
digoxin in healthy volunteers, 107 CYP3A-mediated metabolism by a PPAR-y effect of alosetron on the pharmacokinetics of
effects of tegaserod (HTF 919) on the pharmaco- agonist and its effect on the clinical pharma- fluoxetine, 455
kinetics and pharmacodynamics of digoxin cokinetics of midazolam, an in vivo probe of effect of floxetine on carvedilol pharmaco-
in healthy subjects, 1131 CYP3A activity, 305 kinetics, CYP2D2 activity, and autonomic
evaluating possible pharmacokinetic interactions Drugs balance in heart failure patients, 97
between tobramycin, piperacillin, and a can ['’O]water be used to evaluate drugs?, 11S effect of venlafaxine versus fluoxetine on me-
combination of piperacillin and tazobactam Editorials tabolism of dextromethorphan, a CYP2D6
in patients with various degrees of renal im- nuclear imaging and biomarkers in drug devel- probe, 443
pairment, 979 opment using approved radiopharma- evaluation of the potential phamacokinetic in-
evaluation of the potential pharmacokinetic in- ceuticals, 4S teraction between almotriptan and fluoxe-
teraction between almotriptan and fluoxe-
products approved in the United States for mar- tine in healthy volunteers, 217
tine in healthy volunteers, 217 keting during 2000, 479 Fluticasone propionate
interactions between simvastatin and troglita- the 2000 Alfred P. Wolf Award, 7S single-dose and steady-state pharmacokinetic
zone or pioglitazone in healthy subjects, 573
Education and pharmacodynamic evaluation of thera-
lack of an effect of azithromycin on the disposi-
evaluation of student achievement and educa- peutically clinically equivalent doses of in-
tion of zidovudine and dideoxyinosine in tional outcomes, 1265 haled fluticasone propionate and budesonide,
HIV-infected patients, 210
Eflornithine given as Diskus® or Turbohaler® dry-pow-
lack of citalopram effect on oral digoxin pharm- der inhalers to healthy subjects, 1329
acokinetics, 340 percutaneous absorption and pharmacokinetics
Food
of eflornithine HCL 13.9% cream in women
lack of effect of rosiglitazone on the pharmaco-
with unwanted facial hair, 972 abacavir/lamivudine/zidovudine as a combined
kinetics of oral contraceptives in healthy fe-
formulation tablet: bioequivalence com-
male volunteers, 683 Eletriptan pared with each component administered
lack of interaction between levafloxacin and pharmacokinetics and safety of oral eletriptan concurrently and the effect of food on ab-
oxycodone: pharmacokinetics and drug dis- during different phases of the menstrual cy- sorption, 277
position, 206 cle in healthy volunteers, 1339
effect of low- and high-fat meals on tacrolimus
lack of pharmacokinetic interaction between Elimination absorption following 5 mg single oral doses
rofecoxib and methotrexate in rheumatoid influences of renal function and maturation on to healthy human subjects, 176
arthritis patients, 1120 vancomycin elimination in newborns and
effect of time of meal consumption on bio-
linezolid: pharmacokinetic and pharmaco- infants, 927 availability of a single oral 5 mg tacrolimus
dynamic evalution of coadministration with Enalapril dose, 289
pseudoephedrine HCl, phenylpropanola- pharmacokinetics of enalapril in children and food increases the bioavailability of tolterodine
mine HC], and dextromethorphan HBr, 563 infants with hypertension, 1064 but not effective exposure, 298
linezolid, a novel oxazolidinone antibiotic: as- Eniporide influence of food on the bioavailability of a
sessment of monoamine oxidase inhibition
pharmacokinetic/pharmacodynamic evalua- twice-daily controlled release carbamaze-
using pressor response to oral tyramine, 552
tion of the NHE inhibitor eniporide, 139 pine formulation, 183
pharmaocokinetics, safety, and tolerability of Epilepsy lack of effect of food on the pharmacokinetics of
BAY 12-9566 and nonsteroidal anti-inflam-
matory agents (Naproxen, Ibuprofen) during the use of microPET for the development of neu- an extended-release oxybutynin formula-
coadministration in patients with osteo- ral repair therapeutics: studies in epilepsy tion, 187
and lesion models, 55S Furosemide
arthritis, 330
sevelamer hydrochloride (Renagel®), a Erythromycin omapatrialt: neurohormonal and pharmaco-
nonabsorbed phosphate-binding polymer, race but not age affects erythromycin breath test dynamic profile when administered with
does not interfere with digoxin or warfarin results in older hypertensive men, 324 furosemide, 1291
pharmacokinetics, 193 Estradiol Gabapentin
sevelamer hydrochloride (Renagel®), a phos- pharmacokinetics of norelgestromin and single-dose gabapentin pharmacokinetics and
phate-binding polymer, does not alter the ethinyl estradiol delivered by a contracep- safety in healthy infants and children, 507
pharmacokinetics of two commonly used tive patch (Ortho Evra™/Evra™) under con- Gemtuzumab ozogamicin
antihypertensives in healthy volunteers, 199 ditions of heat, humidity, and exercise, 1301 pharmacokinetics of gemtuzumab ozogamicin,
steady-state pharmacokinetics and tolerability pharmacokinetics of norelgestromin and an antibody-targeted chemotherapy agent
of modafinil given alone or in combination ethinyl estradiol from two consecutive con- for the treatment of patients with acute
with methylphenidate in healthy volunteers, traceptive patches, 1232 myeloid leukemia in first relapse, 1206
895 Etoricoxib Gender
stereoselective effects of bucolome on the dose proportionality of oral etoricoxib, a highly effect of age and gender on the safety,
pharmacokinetics and pharmacodynamics selective cyclooxygenase-2 inhibitor, in tolerability, and pharmacokinetics of BAY
of racemic warfarin, 459 healthy volunteers, 1106 12-9566 in healthy subjects, 764
tegaserod coadministration does not alter the Ezetimibe lack of gender differences and large intrasubject
pharmacokinetics of theophylline in healthy plasma concentration and LDL-C relationship variability of cytochrome P450 activity mea-
subjects, 987 in patients receiving ezetimibe, 943 sured by phenotyping with dextro-
Drug metabolism Fentanyl methorphan, 723
human drug metabolism and the cytochromes single-dose pharmacokinetics of bupropion in
population pharmacokinetics of fentanyl in
P450: application and relevance of vitro mod- adolescents: effects of smoking status and
healthy volunteers, 757
els, 1149 gender, 770
1376
Gentamicin ciency virus type 1 (HIV-1) protease inhibi- tients with human immunodeficiency virus
a dose-ranging study of gentamicin pharmaco- tor, administered as a single oral dose to infection, 1319
kinetics: implications for extended interval healthy male subjects, 386 Japanese
aminoglycoside therapy, 374 pharmacokinetics of intravenous itraconazole effects of low-dose pravastatin on plasma levels
Glucose followed by intraconazole oral solution in of lipids and apolipoproteins in Japanese
the effect of 3-month ingestion of ginkgo biloba patients with human immunodeficiency vi- type II hyperlipoproteinemic subjects with
extract (EGb 761) on pancreatic B-cell func- rus infection, 1319 apolipoprotein E phenotype E3/2, E3/3, and
tion in response to glucose loading in indi- pharmacokinetics and pharmacodynamics of E4/3, 1055
viduals with non-insulin-dependent diabe- thalidomide in HIV patients treated for oral Knowledge discovery
tes mellitus, 600 aphthous ulcers: ACTG protocol 251, 1091 the process of knowledge discovery from large
Grapefruit juice Hypertension pharmacokinetics data sets, 25
effect of grapefruit juice on pharmacokinetics of comparative pharmacokinetics and pharmaco- Lamivudine
microemulsion cyclosporine in African Amer- dynamics of amlodipine in hypertensive pa- abacavir/lamivudine/zidovudine as a com-
ican subjects compared with Caucasian sub- tients with and without type II diabetes bined formulation tablet: bioequivalence
jects: does ethnic difference matter?, 317 mellitus, 1215 compared with each component adminis-
effects of grapefruit juice on pharmacokinetic pharmacokinetics of enalapril in children and tered concurrently and the effect of food on
exposure to indinavir in HIV-positive sub- infants with hypertension, 1064 absorption, 277
jects, 435 Hydrocortisone acetate pharmacokinetics of zidovudine and
GW-420867X pharmacokinetics and rectal bioavailability of lamivudine in neonates following
the bioavailability of the novel nonnucleoside hydrocortisone acetate after single and mul- coadministration of oral doses every 12
reverse transcriptase inhibitor GW-420867X tiple administration in healthy subjects and hours, 732
in unaffected by food in healthy male volun- patients, 536 Lansoprazole
teers, 528 Ibuprofen pharmacodynamic modeling of lansoprazole
pharmacokinetics and tolerability of pharamacokinetics, safety, and tolerability of using an indirect irreversible response
GW420867X, a nonnucleoside reverse tran- BAY 12-9566 and nonsteroidal anti-inflam- model, 251
scriptase inhibitor, following single escalat- matory agents (Naproxen, Ibuprofen) during Levofloxacin
ing doses in healthy male volunteers, 1098 coadministration in patients with lack of interaction between levofloxacin and
Haloperidol osteoarthritis, 330 oxycodone: pharmacokinetics and drug dis-
the effect of intravenous haloperidol on QT in- Imm pp! essive medications position, 206
terval dispersion in critically ill patients: tolerability of newer immunosuppressive medi- Limeadid
comparison with QT interval prolongation cations in a patient with acute intermittent
a novel oxazolidinone antibiotic: assessment of
for assessment of risk of Torsades de porphyria, 113
monoamine oxidase inhibition using
Pointes, 1310 Indinavir pressor response to oral tyramine, 552
Heart failure effects of grapefruit juice on pharmacokinetic Linezolid
effect of fluoxetine on carvedilol pharmaco- exposure to indinavir in HIV-positive sub-
pharmacokinetic and pharmacodynamic evalu-
kinetics, CYP2D2 activity, and autonomic jects, 435 ation of coadministration with
balance in heart failure patients, 97 Infants pseudoephedrine HCl, phenylpro-
pharmacodynamics and pharmacokinetics of caffeine metabolism in premature infants, 620 panolamine HCL, and dextromethorphan
omapatrilat in heart failure, 1280 cardiac adverse effects of early dexamethasone HBr, 563
pharmacokinetics and pharmacodynamics of treatment in preterm infants: a randomized Lorazepam
irbesartan in heart failure, 935 clinical trial, 1075 bioavailability and pharmacokinetics of
Heparin influences of renal function and maturation on lorazepam after intranasal, intravenous, and
low molecular weight heparin-induced liver vancomycin elimination in newborns and intramuscular administration, 1225
toxicity, 691 infants, 927 Magnetic resonance imaging
Herbal medicine pharmacokinetics of enalapril in children and prospects for human pharmacological func-
effect of 3-month ingestion of ginkgo biloba ex- infants with hypertension, 1064 tional magnetic resonance imaging
tract (EGb 761) on pancreatic B-cell function pharmacokinetics of zidovudine and (phMR}), 21S
in response to glucose loading in individu- lamivudine in neonates following Males
als with non-insulin-dependent diabetes coadministration of oral doses every 12 bioavailability of the novel nonnucleoside re-
mellitus, 600 hours, 732
verse transcriptase inhibitor GW420867X is
pharmacokinetics and bioavailability of single-dose gabapentin pharmacokinetics and unaffected by food in healthy male volun-
quercetin glycosides in humans, 492 safety in healthy infants and children, 507 teers, 528
Seville (sour) orange juice: synephrine content Intellectual property effect of food and food composition on alcohol
and cardiovascular effects in normotensive positron-emission tomography tracers as intel- elimination rates in healthy men and
adults, 1059 lectual property, 107S women, 1345
HIV Irbesartan metabolic disposition and pharmacokinetics of
effects of grapefruit juice on pharmacokinetic pharmacokinetics and pharmacodynamics of {“C]-amprenavir, a human immunodefi-
exposure to indinavir in HIV-positive sub- irbesartan in heart failure, 935 ciency virus type 1 (HIV-1) protease inhibi-
jects, 435 tor, administered as a single oral dose to
pharmacokenitics of irbesartan in hypertensive
lack of an effect of azithromycin on the disposi- children and adolescents, 742 healthy male subjects, 386
tion of zidovudine and dideoxyinosine in Itraconazole pharmacokinetics and tolerability of
HIV-infected patients, 210 GW420867X, a nonnucleoside reverse tran-
metabolic disposition and pharmacokinetics of pharmacokinetics of intravenous itraconazole scriptase inhibitor, following single escalat-
(“C]-amprenavir, a human immunodefi- followed by itraconazole oral solution in pa- ing doses in healthy male volunteers, 1098
1377
race but not age affects erythromycin breath test coadministration in patients with p-glycoprotein at the blood-brain barrier and
results in older hypertensive men, 324 osteoarthritis, 330 analysis of drug transport with posi-
Metformin Naratriptan tron-emission tomography, 48S
pharmacokinetics of metformin gastric-reten- pharmacokinetics of naratriptan in adolescent p-glycoprotein is upregulated in peripheral
tive tabelts in healthy volunteers, 655 subjects with a history of mirgaine, 170 T-cell subsets from solid organ transplant re-
cipients, 1271
Methotrexate Nefazodone
Pantoprazole
lack of pharmacokinetic interaction between p-glycoprotein interactions of nefazodone and
rofecoxib and methotrexate in rheumatoid trazodone in cell culture, 708 pharmacodynamic modeling of pantoprazole’s
arthritis patients, 1120 Neuroimaging irreversible effect on gastric acid secretion
in humans and rats, 149
Methylphenidate neuroimaging and drug development: an algo-
Parecoxib
steady-state pharmacokinetics and tolerability rithm for decision making, 64S
of modafinil given alone or in combination NN703 pharmacokinetic study of intramuscular (im)
with methylphenidate in healthy volun- pharmacokinetic and pharmacodynamic mod- parecoxib in normal subjects, 1111
teers, 895 eling of NN703, a growth hormone Parkinson’s disease
Methylprednisolone secretagogue, after a single po dose to hu- monitoring disease progression in Parkinson's
time-variant increase in methylprednisolone man volunteers, 163 disease, 72S
clearance in patients with acute respiratory Norelgestromin Pediatrics
distress syndrome: a population pharmaco- pharmacokinetics of norelgestromin and measurement of acetaminophen-protein ad-
kinetic study, 415 ethinyl estradiol delivered by a contracep- ducts in children and adolescents with
Midazolam tive patch (Ortho Evra™/Evra™) under con- acetaminophen overdoses, 846
lack of correlation between in vitro inhibition of ditioofn hesat , humidity, and exercise, 1301 montelukast dose selection in children ages 2 to
CYP3A-mediated metabolism by a PPAY-y Norelgestromin 5 years: comparison of population
agonist and its effect on the clinical pharmacokinetics of norelgestromin and pharmacokinetics and tolerability of buspirone
pharmacokinetics of midazolam, an in vivo ethinyl estradiol from two consecutive con- during oral administration to children and
probe of CYP3A activity, 305 traceptive patches, 1232 adolescents with anxiety disorder and nor-
midazolam disposition in patients undergoing mal healthy adults, 1351
Nuclear imaging
continuous venovenous hemodialysis, 959 pharmacokinetics between children and adults,
nuclear imaging and biomarkers in drug devel-
single-dose pharmacokinetics of midazolam opment using approved radiopharma- 612
and its primary metabolite in pediatric pa- ceuticals, 4S pharmacokinetics of enalapril in children and
tients after oral and intravenous administra- infants with hypertension, 1064
Omapatrilat
tion, 1359
omapatrilat: neurohoromonal and pharma- pharmacokinetics of irbesartan in hypertensive
Migraine children and adolescents, 742
codynamic profile when administered with
pharmacokinetics of naratriptan in adolescent furosemide, 1291 pharmacokinetics of naratriptan in adolescent
subjects with a history of migraine, 170 subjects with a history of migraine, 170
oral bioavailability and disposition of [°C]
Minocycline omapatrilat in healthy subjects, 833 pharmacokinetics of zidovudine and
risk of liver damage associated with mino- lamivudine in neonates following
pharmacodynamics and pharmacokinetics of
cycline: a comparative study, 852 coadministration of oral doses every 12
omapatrilat in heart failure, 1280
Modafinil hours, 732
Orange juice
steady-state pharmacokinetics and tolerability of single-dose gabapentin pharmacokinetics and
modafinil given alone or in combination with Seville (sour) orange juice: synephrine content safety in healthy infants and children, 507
and cardiovascular effects in normotensive
methylphenidate in healthy volunteers, 895 single-dose pharmacokinetic of bupropion in
adults, 1059
Multidrug resistance adolescents: effects of smoking status and
Osteoporosis therapy gender, 770
reversal of multidrug resistance with LY335979:
functional analysis of p-glycoprotein-medi- comparative safety of bone remodeling agents single-dose pharmacokinetics of midazolam
with a focus on osteoporosis therapies, 239
ated transport activity and its modulation in and its primary metabolite in pediatric pa-
vivo, 29S Oxybutynin tients after oral and intravenous administra-
Mycophenolate effects of tolterodine, trospium chloride, and tion, 1359
oxybutynin on the central nervous system, single-dose pharmacokinetics of sotalol in a pe-
comparison of azathioprine and mycophenolate
636 diatric population with supraventricular
mofetil for the prevention of acute rejection
in recipients of pancreas transplantation, lack of effect of food on the pharmacokinetics of and/or ventricular tachyarrhythmia, 35
861 an extended-release oxybutynin formula- PET
Mycophenolic acid tion, 187 the use of microPET for the development of neu-
Oxycodone ral repair therapeutics: studies in epilepsy
pharmacokinetics of mycophenolic acid after
double-blind randomized comparison of the an- and lesion models, 55S
mycophenolate mofetil administration in
liver transplant patients treated with algesic and pharmacokinetic profiles of con- Pharmacodynamics
trolled- and immediate-release oral oxyco-
tacrolimus, 268 abacavir/lamivudine/zidovudine as a com-
Myocardial infaraction done in cancer pain patients, 500 bined formulation tablet: bioequivalence
Oxycodone compared with each component adminis-
prevention of a first myocardial infarction, 359
lack of interaction between levofloxacin and tered concurrently and the effect of food on
Naproxen oxycodone: pharmacokinetics and drug absorption, 277
a look at the safety profile of over-the-counter dispostion, 206 bioavailability and pharmacokinetics of
naproxen sodium: a meta-analysis, 127 P-glycoprotein (P-gp) lorazepam after intranasal, intravenous, and
pharmacokinetics, safety, and tolerability of interactions of nefazodone and trazodone in cell intramuscular administration, 1225
BAY 12-9566 and nonsteroidal anti-inflam-
culture, 708
matory agents (Naproxen, Ibuprofen) during
1378
comparative multidose pharmacokinetic study omapatrilat: neurohormonal and pharmaco- pharmacokinetics and pharmacodynamics of
of buspirone extended-release tablets with a dynamic profile when administered with dexamethasone sodium-m-sulfobenzoate
reference immediate-release product, 886 furosemide, 1291 (DS) after intravenous and intramuscular
comparative pharmacokinetics and overview of the pharmacokinetics of cilomilast administration: a comparison with dexa-
pharmacodynamics of amlodipine in hy- (Ariflo®), a new orally active phospho- methasone phosphate (DP), 425
pertensive patients with and without type II diesterase 4 inhibitor, in healthy young and pharmacokinetics and pharmacodynamics of
diabetes mellitus, 1215 elderly volunteers, 950 irbesartan in heart failure, 935
comparative tacrolimus pharmacokinetics: nor- percutaneous absorption and pharmacokinetics pharmacokinetics and pharmacodynamics of
mal versus mild hepatically impaired sub- of eflornithine HCL 13.9% cream in women recombinant FGF-2 in a phase! trial in coro-
jects, 628 with unwanted facial hair, 972 nary artery disease, 378
dose proportionality of oral etoricoxib, a highly pharmacodynamic modeling of lansoprazole pharmacokinetics and pharmacodynamics of
selective cyclooxygenase-2 inhibitor, in using an indirect irreversible response thalidomide in HIV patients treated for oral
healthy volunteers, 1106 model, 251 aphthous ulcers: ACTG Protocol 251, 1091
dose-ranging study of gentamicin pharma- pharmacodynamic modeling of pantoprazole’s pharmacokinetics and rectal bioavialability of
cokinetics: implications for extended inter- irreversible effect on gastric acid secretion hydrocortisone acetate after single and mul-
val aminoglycoside therapy, 374 in humans and rats, 149 tiple administration in healthy subjects and
effect of age and gender on the safety, pharmacodynamics and pharmacokinetics of patients, 536
tolerability, and pharmacokinetics of BAY omapatrilat in heart failure, 1280 pharmacokinetics and safety of FFR-rF VIla after
12-9566 in healthy subjects, 764 pharmacokinetic and pharmacodynamic mod- single doses in healthy subjects, 880
effects of converting from simvastatin to eling of NN703, a growth hormone pharmacokinetics and safety of oral eletriptan
atorvastatin on plasminogen activator in- secretagogue, after a single po dose to hu- during different phases of the menstrual cy-
hibitor type-1, 779 man volunteers, 163 cles in healthy volunteers, 1339
effect of food and food composition on alcohol pharmacokinetic of buspirone extended-release pharmacokinetics of tilidine in terminal renal
elimination rates in healthy men and tablets: a single-dose study, 783 failure, 79
women, 1345 pharmacokinetic study of intramuscular (IM) pharmacokinetics and tolerability of buspirone
effect of intravenous haloperidol on QT interval parecoxib sodium in normal subjects, 1111 during oral administration to children and
dispersion in critically ill patients: compari- pharmacokinetic-pharmacodynamic modeling adolescents with anxiety disorder and nor-
son with QT interval prolongation for as- of the antilipolytic effects of an adenosine mal healthy adults, 1351
sessment of risk of Torsades de Pointes, receptor agonist in healthy volunteers, 61 pharmacokinetics and tolerability of
1310 pharmacokinetic-pharmacodynamic modeling GW420867X, a nonnucleoside reverse tran-
effect of low- and high-fat meals on tacrolimus of atracurium in intensive care patients, 44 scriptase inhibitor, following single escalat-
absorption following 5 mg single oral doses ing doses in healthy male volunteers, 1098
pharmacokinetic/pharmacodynamic evalua-
to healthy human subjects, 176 tion of the NHE inhibitor eniporide, 139 pharmacokinetics-pharmacodynamic model-
effect of time of meal consumption on ing of the electroencephalogram effects of
pharmacokinetics, excretion, and mass balance
bioavailability of a single oral 5 mg of “C after administration of “C-choles- scopolamine in healthy volunteers, 51
tacrolimus dose, 289 terol-labeled ambisome to healthy volun- pharmacokinetics-pharmacodynamic model-
effects of oral prasterone (dehydroepian- teers, 963 ing on rivastigmine, a cholinesterase inhibi-
drosterone) on single-dose pharmaco- tor, in patients with Alzheimer’s disease,
pharmacokinetics of colistin in patients with
kinetics of oral cystic fibrosis, 645 1082
prednisone and cortisol suppression in normal plasma concentration and LDL-C relationship
pharmacokinetics of CS-866, a new angiotensin
women, 1195 in patients receiving ezetimibe, 943
II receptor blocker, in healthy subjects, 515
effects of tolterodine, trospium chloride, and population pharmacokinetics of fentanyl in
pharmacokinetics of gemtuzumab ozogamicin,
oxybutynin on the central nervous system, healthy volunteers, 757
an antibody-targeted chemotherapy agent
636 for the treatment of patients with acute prednisolone pharmacokinetics and
food increases the bioavailability of tolterodine myeloid leukemia in first relapse, 1206 pharmacodynamics in relation to sex and
but not effective exposure, 298 race, 1180
pharmacokinetics of intravenous itraconazole
influence of food on the bioavailability of a followed by itraconazole oral solution in pa- reduction of LDL cholesterol in patients with
twice-daily controlled release carbamaze- tients with human immunodeficiency virus primary hypercholesterolemia ky SCH
pine formulation, 183 infection, 1319 48461: results of am ulticenter dose-ranging
intravenous safety and pharmacokinetics of a pharmacokinetics of metformin gastric-reten- study, 70
novel dimerizer drug, AP1903, in healthy tive tablets in healthy volunteers, 655 single-dose pharmacokinetics of atrasentan, an
volunteers, 870 endothelin-A receptor antagonist, 397
pharmacokinetics of mycophenolic acid after
lack of effect of food on the pharmacokinetics of mycophenolate mofetil administration in single-dose pharmacokinetics of bupropion in
an extended-release oxybutynin formula- liver transplant patients treated with adolescents: effects of smoking status and
tion, 187 tacrolimus, 268 gender, 770
metabolic disposition and pharmacokinetics of pharmacokinetics of naratriptan in adolescent single-dose and steady-state pharmacokinetic
(“C]-amprenavir, a human immunodefi- subjects with a history of migraine, 170 and pharmacodynamic evaluation of thera-
ciency virus type 1 (HIV-1) protease inhibi- peutically clinically equivalent doses of in-
pharmacokinetics of norelgestromin and
tor, administered as a single oral dose to haled fluticasone propionate and
ethinyl estradiol delivered by a contracep-
healthy male subjects, 386 budesonide, given as Diskus® or
tive patch (Ortho Evra™/Evra™) under con-
midazolam disposition in patients undergoing ditions of heat, humidity, and exercise, 1301 Turbohaler® dry-powder inhalers to
continuous venovenous hemodialysis, 959 healthy subjects, 1329
pharmacokinetics of norelgestromin and
multiple-dose pharmacokinetics and safety of ethinyl estradiol from two consecutive con- theophylline metabolism after cardiac surgery,
two regimens of quinupristin/dalfopristin traceptive patches, 1232 157
(Synercid®) in healthy volunteers, 404
1379
time-variant increase in methylprednisolone effect of low- and high-fat meals on tacrolimus pharmacokinetic/pharmacodynamic evalua-
clearance in patients with acute respiratory absorption following 5 mg single oral doses tion of the NHE inhibitor eniporide, 139
distress syndrome: a_ population to healthy human subjects, 176 pharmacokinetics and pharmacodynamics of
pharmacokinetic study, 415 effect of time of meal consumption on dexamethasone sodium-m-sulfobenzoate
Pharmacoepidemiology bioavailability of a single oral 5 mg (DS) after intravenous and intramuscular
acid-suppressive therapy use associated with tacrolimus dose, 289 administration: a comparison with dexa-
antihypertensive agents, 750 effects of converting from simvastatin to methasone phosphate (DP), 425
comparison of azathioprine and mycophenolate atorvastatin on plasminogen activator in- pharmacokinetics and pharmacodynamics of
mofetil for the prevention of acute rejection hibitor type-1, 779 irbesartan in heart failure, 935
in recipients of pancreas transplantation, effects of oral prasterone (dehydroepian- pharmacodynamics and pharmacokinetics of
861 drosterone) on single-dose pharmaco- omapatrilat in heart failure, 1280
effects of low-dose pravastatin on plasma levels kinetics of oral prednisone and cortisol sup- pharmacokinetics and pharmacodynamics of
of lipids and apolipoproteins in Japanese pression in normal women, 1195 recombinant FGF-2 ina phase I trial in coro-
type II hyperlipoproteinemic subjects with food increases the bioavailability of tolterodine nary artery disease, 378
apolipoprotein E phenotype E3/2, E3/3, and but not effective exposure, 298 pharmacokinetics and pharmacodynamics of
E4/3, 1055 influence of food on the bioavailability of a thalidomide in HIV patients treated for oral
risk of liver damage associated with twice-daily controlled release carbamaze- aphthous ulcers: ACTG Protocol 251, 1091
minocycline: a comparative study, 852 pine formulation, 183 pharmacokinetics and rectal bioavailability of
Pharmacokinetics intravenous safety and pharmacokinetics of a hydrocortisone acetate after single and mul-
abacavir/lamivudine/zidovudine as a com- novel dimerizer drug, AP1903, in healthy tiple administration in healthy subjects and
bined formulation tablet: bioequivalence volunteers, 870 patients, 536
compared with each component adminis- lack of effect of food on the pharmacokinetics of pharmacokinetics and safety of FFR-rF VIla after
tered concurrently and the effect of food on an extended-release oxybutynin formula- single doses in healthy subjects, 880
absorption, 277 tion, 187 pharmacokinetics and safety of oral eletriptan
bioavailability of the novel nonnucleoside re- metabolic disposition and pharmacokinetics of during different phases of the menstrual cy-
verse transcriptase inhibitor GW 420867X is {“C]-amprenavir, a human immunodefi- cles in healthy volunteers, 1339
unaffected by food in healthy male volun- ciency virus type 1 (HIV-1) protease inhibi- pharmacokinetics and tolerability of buspirone
teers, 528 tor, administered as a single oral dose to during oral administration to children and
bioavailability and pharmacokinetics of healthy male subjects, 386 adolescents with anxiety disorder and nor-
lorazepam after intranasal, intravenous, and midazolam disposition in patients undergoing mal healthy adults, 1351
intramuscular administration, 1225 continuous venovenous hemodialysis, 959 pharmacokinetics and tolerability of
comparative multidose pharmacokinetics study multiple-dose pharmacokinetics and safety of GW420867X, a nonnucleoside reverse tran-
of buspirone extended-release tablets with a two regimens of quinupristin/dalfopristin scriptase inhibitor, following single escalat-
reference immediate-release product, 886 (Synercid®) in healthy volunteers, 404 ing doses in healthy male volunteers, 1098
comparative pharmacokinetics and omapatrilat: neurohoromonal and pharmaco- pharmacokinetics of buspirone extended-release
pharmacodynamics of amlodipine in hy- dynamic profile when administered with tablets: a single-dose study, 783
pertensive patients with and without type II furosemide, 1291 pharmacokinetics of CS-866, a new angiotensin
diabetes mellitus, 1215 overview of the pharmacokinetics of cilomilast Il receptor blocker, in healthy subjects, 515
effects of tolterodine, trospium chloride, and (Ariflo®), a new, orally active phospho- pharmacokinetics of colistin in patients with
oxybutynin on the central nervous system, diesterase 4 inhibitor, in healthy young and cystic fibrosis, 645
636 elderly volunteers, 950 pharmacokinetics of gemtuzumab ozogamicin,
comparative tacrolimus pharmacokinetics: nor- percutaneous absorption and pharmacokinetics an antibody-targeted chemotherapy agent
mal versus mildly hepatically impaired sub- of eflornithine HCL 13.9% cream in women for the treatment of patients with acute
jects, 628 with unwanted facial hair, 972 myeloid leukemia in first relapse, 1206
dichloroacetate: population pharmacokinetics pharmacodynamic modeling of lansoprazole pharmacokinetics of intravenous itraconazole
with a pharmacodynamic sequential link using an indirect irreversible response followed by itraconazole oral solution in pa-
model, 259 model, 251 tients with human immunodeficiency virus
dose proportionality of oral etoricoxib, a highly pharmacodynamic modeling of pantoprazole’s infection, 1319
selective cyclooxygenase-2 inhibitor, in irreversible effect on gastric acid secretion pharmacokinetics of metformin gastric-reten-
healthy volunteers, 1106 in humans and rats, 149 tive tablets in healthy volunteers, 655
dose-ranging study of gentamicin pharma- pharmacokinetics, excretion, and mass balance pharmacokinetics of mycophenolic acid after
cokinetics: implications for extended inter- of “C after administration of “C-choles- mycophenolate mofetil administration in
val aminoglycoside therapy, 374 terol-labeled ambisome to healthy volun- liver transplant patients treated with
effect of age and gender on the safety, teers, 963 tacrolimus, 268
tolerability, and pharmacokinetics of BAY pharmacokinetic and parmacodynamic model- pharmacokinetics of naratriptan in adolescent
12-9566 in healthy subjects, 764 ing of NN703, a growth hormone subjects with a history of migraine, 170
effect of food and food composition on alcohol secretagogue, after a single po dose to hu- pharmacokinetics of norelgestromin and
elimination rates in healthy men and man volunteers, 163 ethinyl estradiol delivered by a contracep-
women, 1345 pharmacokinetic study of intramuscular (IM) tive patch (Ortho Evra™/Evra™) under con-
effect of intravenous haloperidol on QT interval parecoxib sodium in normal subjects, 1111 ditions of heat, humidity, and exercise, 1301
dispersion in critically ill patients: compari- pharmacokinetic-pharmacodynamic modeling pharmacokinetics of norelgestromin and
son with QT interval prolongation for as- of the antilipolytic effects of an adenosine ethinyl estradiol from two consecutive con-
sessment of risk of Torsades de Pointes, receptor agonist in healthy volunteers, 61 traceptive patches, 1232
1310 pharmacokinetic-pharmacodynamic modeling pharmacokinetics of tilidine in terminal renal
of atracurium in intensive care patients, 44 failure, 79